Company: MDCXW
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001062993-25-014844
Chunk: 2

Company: Medicus Pharma Ltd.
Filing Date: 2025-08-22
Form: 424B3
Chunk 2
---
 if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 3.02. Unregistered Sales of Equity Securities. Pursuant to the previously disclosed Standby Equity Purchase Agreement (the "SEPA"), dated February 10, 2025, between Medicus Pharma Ltd. (the "Company") and YA II PN, Ltd. ("Yorkville"), the Company completed sales of its common shares (the "Common Shares") to Yorkville (collectively, the "SEPA Advances") as disclosed in the table below:

| Date of Sale    | Number of Common 
           Shares | Price per share | Approximate Aggregate 
         Consideration |
| July 30, 2025   |           50,000 |         $2.8963 |              $144,815 |
| August 12, 2025 |          200,000 |         $2.0425 |              $408,500 |
| August 12, 2025 |           52,504 |           $1.94 |              $101,858 |
| August 18, 2025 |          200,000 |         $1.9664 |              $393,280 |
| August 18, 2025 |            7,150 |           $1.94 |               $13,871 |
| August 21, 2025 |          300,000 |         $1.9638 |              $589,140 |
| Total           |          809,654 |                 |            $1,651,464 |

The Company may cause Yorkville to purchase additional Common Shares under the SEPA from time to time, subject to the satisfaction or waiver of the conditions and limitations set forth in the SEPA. The Company intends to use part of the net proceeds from the SEPA Advances to prepay a portion of the debentures the Company has outstanding with Yorkville, as described in that certain Current Report on Form 8-K dated June 20, 2025. The Common Shares were issued and sold to Yorkville in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), afforded by Section 4(a)(2) of the Securities Act. The Company is relying on this exemption from registration based in part on representations made by Yorkville in the SEPA. York